HIV Therapies in the EU:  Gauging the potential of Atripla

Specialties:

HIV Therapies in the EU: Gauging the Potential of Atripla

A Survey of Fifty Physicians

May 2008

Price $2500

Deliverable: Survey with key findings.

Study Description:

Topic	HIV Treatment Outlook
Respondent Type	Physicians
Specialty	Infectious disease/HIV specialists
Region	Geographical mix
Methodology	Online survey, self-administered via a Panel Intelligence website § Duration: 30 minutes § Size: 50 respondents § Fielding dates: April 21, 2008 to April 30, 2008

Study Objectives:

To understand current practices regarding the use of HIV therapies in the EU and to assess the market potential of Atripla.

§ Determine current practice patterns in HIV.

§ Quantify usage and market potential of agents in HIV patients.

§ Gain understanding of recent data announced from the DAD and ACTG studies.

§ Assess the impact of Atripla’s label on its initial launch.

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

§ 50 physicians (infectious disease, HIV specialists) in the EU

§ 2 to 30 years of experience post-residency

§ Minimum 40% professional time spent in clinical practice

§ Currently treat at least 50 (Germany and United Kingdom) HIV patients

To purchase this report or request additional information, contact:

Reports become free one year after the publication date.

about us